Literature DB >> 27546841

Pancreatic Cancer: A Review.

Cinthya S Yabar1, Jordan M Winter2.   

Abstract

Pancreatic cancer is now the third leading cause of cancer related deaths in the United States, yet advances in treatment options have been minimal over the past decade. In this review, we summarize the evaluation and treatments for this disease. We highlight molecular advances that hopefully will soon translate into improved outcomes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Evaluation; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Treatment

Mesh：

Substances：

Year:  2016        PMID： 27546841     DOI： 10.1016/j.gtc.2016.04.003

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  30 in total

1.  Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.

Authors:  Majid Momeny; Zivar Alishahi; Haniyeh Eyvani; Fatemeh Esmaeili; Azam Zaghal; Parisa Ghaffari; Javad Tavakkoly-Bazzaz; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2019-09-06       Impact factor: 6.730

2.  The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.

Authors:  Yunpeng Sun; Pengfei Wang; Wenjun Yang; Yunfeng Shan; Qiyu Zhang; Huanhuan Wu
Journal:  Cancer Biol Ther       Date:  2019-03-27       Impact factor: 4.742

3.  Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy.

Authors:  Robert S O'Neill; Lyn L Lam; Parthsinh Solanki; Robyn Levingston; David Thomas
Journal:  Cancer Rep (Hoboken)       Date:  2020-08-09

4.  The influence of marital status on survival of gallbladder cancer patients: a population-based study.

Authors:  Xinxing Li; Ye Liu; Yi Wang; Canping Ruan; Haolu Wang; Xiaowen Liang; Yanping Sun; Zhiqian Hu
Journal:  Sci Rep       Date:  2017-07-13       Impact factor: 4.379

5.  MicroRNA co-expression networks exhibit increased complexity in pancreatic ductal compared to Vater's papilla adenocarcinoma.

Authors:  Tommaso Mazza; Massimiliano Copetti; Daniele Capocefalo; Caterina Fusilli; Tommaso Biagini; Massimo Carella; Antonio De Bonis; Nicola Mastrodonato; Ada Piepoli; Valerio Pazienza; Evaristo Maiello; Fabio Francesco di Mola; Pierluigi di Sebastiano; Angelo Andriulli; Francesca Tavano
Journal:  Oncotarget       Date:  2017-10-31

6.  Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation.

Authors:  Hengqing Zhu; Qing Li; Yulan Zhao; Hong Peng; Liangyun Guo; Jing Zhu; Zi Jiang; Zhaoxia Zeng; Bin Xu; Sisi Chen
Journal:  Oncogene       Date:  2021-06-17       Impact factor: 9.867

7.  A Single-institution Experience with Open Irreversible Electroporation for Locally Advanced Pancreatic Carcinoma.

Authors:  Li Yan; Yong-Liang Chen; Ming Su; Tian Liu; Kai Xu; Feng Liang; Wan-Qing Gu; Shi-Chun Lu
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

8.  Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.

Authors:  Yi-Fan Xu; Bethany N Hannafon; Yan D Zhao; Russell G Postier; Wei-Qun Ding
Journal:  Oncotarget       Date:  2017-08-18

9.  Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).

Authors:  Zi-Jun Xiang; Tao Hu; Yun Wang; Hao Wang; Lin Xu; Ning Cui
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

10.  Zyflamend induces apoptosis in pancreatic cancer cells via modulation of the JNK pathway.

Authors:  Dexter L Puckett; Mohammed Alquraishi; Dina Alani; Samah Chahed; Dallas Donohoe; Brynn Voy; Jay Whelan; Ahmed Bettaieb
Journal:  Cell Commun Signal       Date:  2020-08-14       Impact factor: 5.712
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.